|
1
|
Zaccardi F, Webb DR, Yates T and Davies
MJ: Pathophysiology of type 1 and type 2 diabetes mellitus: A
90-year perspective. Postgrad Med J. 92:63–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weuve J, Hebert LE, Scherr PA and Evans
DA: Prevalence of Alzheimer disease in US states. Epidemiology.
26:e4–e6. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cumming TB, Marshall RS and Lazar RM:
Stroke, cognitive deficits, and rehabilitation: still an incomplete
picture. Int J Stroke. 8:38–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kosaraju J, Gali CC, Khatwal RB, Dubala A,
Chinni S, Holsinger RM, Madhunapantula VS, Muthureddy Nataraj SK
and Basavan D: Saxagliptin: A dipeptidyl peptidase-4 inhibitor
ameliorates streptozotocin induced Alzheimer's disease.
Neuropharmacology. 72:291–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le Couteur DG, Wahl D and Naismith SL:
Comorbidity and vascular cognitive impairment-no dementia (VCI-ND).
Age Ageing. 46:705–707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi D, Chen X and Li Z: Diagnostic test
accuracy of the Montreal Cognitive Assessment in the detection of
post-stroke cognitive impairment under different stages and
cutoffs: a systematic review and meta-analysis. Neurol Sci.
39:705–716. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kosaraju J, Murthy V, Khatwal RB, Dubala
A, Chinni S, Muthureddy Nataraj SK and Basavan D: Vildagliptin: An
anti-diabetes agent ameliorates cognitive deficits and pathology
observed in streptozotocin-induced Alzheimer's disease. J Pharm
Pharmacol. 65:1773–1784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kornelius E, Lin CL, Chang HH, Li HH,
Huang WN, Yang YS, Lu YL, Peng CH and Huang CN: DPP-4 Inhibitor
linagliptin attenuates Aβ-induced cytotoxicity through activation
of AMPK in neuronal cells. CNS Neurosci Ther. 21:549–557. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Graaf C, Donnelly D, Wootten D, Lau J,
Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, et al:
Glucagon-like peptide-1 and its class B G protein-coupled
receptors: A long march to therapeutic successes. Pharmacol Rev.
68:954–1013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tramutola A, Arena A, Cini C, Butterfield
DA and Barone E: Modulation of GLP-1 signaling as a novel
therapeutic approach in the treatment of Alzheimer's disease
pathology. Expert Rev Neurother. 17:59–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hansen HH, Barkholt P, Fabricius K,
Jelsing J, Terwel D, Pyke C, Knudsen LB and Vrang N: The GLP-1
receptor agonist liraglutide reduces pathology-specific tau
phosphorylation and improves motor function in a transgenic
hTauP301L mouse model of tauopathy. Brain Res. 1634:158–170. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Candeias EM, Sebastião IC, Cardoso SM,
Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR,
Moreira PI and Duarte AI: Gut-brain connection: The neuroprotective
effects of the anti-diabetic drug liraglutide. World J Diabetes.
6:807–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Wang L, Jiang R, Xu Y, Zhao X and
Li Y: Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial
learning and memory ability. Exp Ther Med. 12:2885–2892. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Isik AT, Soysal P, Yay A and Usarel C: The
effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions
in elderly diabetic patients with or without Alzheimer's disease.
Diabetes Res Clin Pract. 123:192–198. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin Y, Gao D, Wang Y, Wang ZH, Wang X, Ye
J, Wu D, Fang L, Pi G, Yang Y, et al: Tau accumulation induces
synaptic impairment and memory deficit by calcineurin-mediated
inactivation of nuclear CaMKIV/CREB signaling. Proc Natl Acad Sci
USA. 113:E3773–E3781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogedengbe S, Ezeani IU and Aihanuwa E:
Comparison of clinical and biochemical variables in type 2 diabetes
mellitus patients and their first-degree relatives with metabolic
syndrome in Benin City, Nigeria: A cross sectional case controlled
study. Endocr Regul. 50:32–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blum S, Luchsinger JA, Manly JJ, Schupf N,
Stern Y, Brown TR, DeCarli C, Small SA, Mayeux R and Brickman AM:
Memory after silent stroke: hippocampus and infarcts both matter.
Neurology. 78:38–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ciesielska N, Sokołowski R, Mazur E,
Podhorecka M, Polak-Szabela A and Kędziora-Kornatowska K: Is the
Montreal Cognitive Assessment (MoCA) test better suited than the
Mini-Mental State Examination (MMSE) in mild cognitive impairment
(MCI) detection among people aged over 60? Meta-analysis. Psychiatr
Pol. 50:1039–1052. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rizzo MR, Marfella R, Barbieri M, Boccardi
V, Vestini F, Lettieri B, Canonico S and Paolisso G: Relationships
between daily acute glucose fluctuations and cognitive performance
among aged type 2 diabetic patients. Diabetes Care. 33:2169–2174.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Watson GS and Craft S: Modulation of
memory by insulin and glucose: Neuropsychological observations in
Alzheimer's disease. Eur J Pharmacol. 490:97–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng G, Zheng Y, Xiong Z, Ye B, Tao J and
Chen L: Effect of Baduanjin exercise on cognitive function in
patients with post-stroke cognitive impairment: Study protocol for
a randomised controlled trial. BMJ Open. 8:e0209542018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosenberg GA: Extracellular matrix
inflammation in vascular cognitive impairment and dementia. Clin
Sci (Lond). 131:425–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou JB, Bai L, Wang Y and Yang JK: The
benefits and risks of DPP4-inhibitors vs. sulfonylureas for
patients with type 2 diabetes: Accumulated evidence from randomised
controlled trial. Int J Clin Pract. 70:132–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loh HH, Yee A, Loh HS, Sukor N and
Kamaruddin NA: Comparative studies of dipeptidyl peptidase 4
inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients
who fast in the month of Ramadan: A systematic review and
meta-analysis. Prim Care Diabetes. 10:210–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bekiari E, Rizava C, Athanasiadou E,
Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P
and Tsapas A: Systematic review and meta-analysis of vildagliptin
for treatment of type 2 diabetes. Endocrine. 52:458–480. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xi YD, Zhang DD, Ding J, Yu HL, Yuan LH,
Ma WW, Han J and Xiao R: Genistein inhibits Aβ25-35-induced
synaptic toxicity and regulates CaMKII/CREB pathway in SH-SY5Y
cells. Cell Mol Neurobiol. 36:1151–1159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kosaraju J, Holsinger RMD, Guo L and Tam
KY: Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates
cognitive deficits and pathology in the 3×Tg-AD mouse model of
Alzheimer's disease. Mol Neurobiol. 54:6074–6084. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Leon MJ, Pirraglia E, Osorio RS,
Glodzik L, Saint-Louis L, Kim HJ, Fortea J, Fossati S, Laska E,
Siegel C, et al Alzheimer's Disease Neuroimaging Initiative;
National Alzheimer's Coordinating Center, : The nonlinear
relationship between cerebrospinal fluid Aβ42 and tau in
preclinical Alzheimer's disease. PLoS One. 13:e01912402018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mayeux R, Honig LS, Tang MX, Manly J,
Stern Y, Schupf N and Mehta PD: Plasma A[beta]40 and A[beta]42 and
Alzheimer's disease: Relation to age, mortality, and risk.
Neurology. 61:1185–1190. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rembach A, Faux NG, Watt AD, Pertile KK,
Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, et
al AIBL research group, : Changes in plasma amyloid beta in a
longitudinal study of aging and Alzheimer's disease. Alzheimers
Dement. 10:53–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Janelidze S, Stomrud E, Palmqvist S,
Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir
CA, Baker D, et al: Plasma β-amyloid in Alzheimer's disease and
vascular disease. Sci Rep. 6:268012016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ebtehaj S, Gruppen EG, Parvizi M, Tietge
UJF and Dullaart RPF: The anti-inflammatory function of HDL is
impaired in type 2 diabetes: Role of hyperglycemia, paraoxonase-1
and low grade inflammation. Cardiovasc Diabetol. 16:1322017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Prati F, Bartolini M, Simoni E, De Simone
A, Pinto A, Andrisano V and Bolognesi ML: Quinones bearing
non-steroidal anti-inflammatory fragments as multitarget ligands
for Alzheimer's disease. Bioorg Med Chem Lett. 23:6254–6258. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mun MJ, Kim JH, Choi JY and Jang WC:
Genetic polymorphisms of interleukin genes and the risk of
Alzheimer's disease: An update meta-analysis. Meta Gene. 8:1–10.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim YS, Lee KJ and Kim H: Serum tumour
necrosis factor-α and interleukin-6 levels in Alzheimer's disease
and mild cognitive impairment. Psychogeriatrics. 17:224–230. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Q, Qian G and Ding Z: Xuemaitong
granules attenuate carotid atherosclerosis by decreasing the
expression of CD14+CD16+ monocytes, IL-6,
TNF-α, and hsCRP. Genet Mol Res. 13:7519–7527. 2014. View Article : Google Scholar : PubMed/NCBI
|
